Sotrovimab

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

Retrieved on: 
수요일, 11월 8, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Bill & Melinda Gates Foundation, Fintech, Sotrovimab, SARS-CoV-2, Deloitte Technology Fast 500, Bill, Immune system, Antibody, MBA, Telecommunications, GSK, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America.
  • This is the first time in the 29-year history of the Deloitte Technology Fast 500 program that a company has topped the list for two consecutive years.
  • “Ranking number one for the second year in a row on the Deloitte Technology Fast 500 list reflects Vir’s ability to leverage our world class immunology expertise to engineer human antibodies into very powerful medicines,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer.
  • “This growth success is fueling our clinical programs while also strengthening our scientific platforms and pipeline so we can continue to power the immune system to transform lives.”

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
목요일, 8월 3, 2023
HIV Vaccine Trials Network, GSK, Corporate Affairs, EASL, Sotrovimab, HIV, Investment, Influenza, Marketing, Conference call, Head, Hook effect, National Institute of Allergy and Infectious Diseases, COVID-19, Hepatitis, PEG, CHB, MBA, Infection, Bill & Melinda Gates Foundation, Bangladesh Technical Education Board, JJI, Congress, Conditional sentence, Patient, Vir, SAN, HPV, Bill, European Association of Urology, AI, NIAID, Johnson & Johnson, Viral hepatitis, Vaccine, CHD, HCMV, Conference, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Management

ET, Aug. 3, 2023 –

Key Points: 
  • ET, Aug. 3, 2023 –
    SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • Vir expects the Phase 1 trial for VIR-1388, a novel T cell vaccine for the prevention of HIV, to begin dosing in Q3 2023.
  • In June, Sasha Damouni Ellis joined Vir as Executive Vice President and Chief Corporate Affairs Officer.
  • Revenues: Total revenues for the quarter ended June 30, 2023, were $3.8 million compared to $(40.6) million for the same period in 2022.

Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)

Retrieved on: 
수요일, 2월 22, 2023
Marketing, Sotrovimab, Risk, Therapy, NICE, SAN, GSK, Nirmatrelvir/ritonavir, COVID-19, Patient, SARS-CoV-2, Pharmaceutical industry

Due to existing inventory, no meaningful additional sales of sotrovimab in the UK are anticipated in 2023.

Key Points: 
  • Due to existing inventory, no meaningful additional sales of sotrovimab in the UK are anticipated in 2023.
  • “We welcome the final draft guidance from NICE which we believe is particularly meaningful as the organization’s recommendations are informed by independent committees that aim to provide guidance to healthcare professionals on the best care options available to benefit their patients,” said George Scangos, Ph.D., Chief Executive Officer of Vir.
  • NICE expects to publish its final recommendations on medicines to treat COVID-19 in March 2023.
  • Sotrovimab has obtained emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy®️) for early treatment of COVID-19, supplying more than 40 countries.

GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab

Retrieved on: 
수요일, 7월 28, 2021
Life sciences, Health sciences, Biotechnology, Pharmaceutical industry, Antiviral drugs, COVID-19 drug development, Pharmacy, Food and Drug Administration, United States Public Health Service, Biologics license application, Sotrovimab, Biopharmaceutical

The Joint Procurement Agreement enables participating European Union (EU) Member States to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with COVID-19 who may benefit from early treatment with sotrovimab.

Key Points: 
  • The Joint Procurement Agreement enables participating European Union (EU) Member States to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with COVID-19 who may benefit from early treatment with sotrovimab.
  • GSK and Vir have secured supply agreements with multiple governments around the world and will continue those efforts as the pandemic continues to evolve.
  • GSK and Vir have announced plans to submit a Biologics License Application (BLA) to the U.S. FDA in the second half of 2021.
  • GSK and Vir are committed to ongoing evaluation of sotrovimab as the COVID-19 landscape continues to evolve at different rates across the globe and new variants of concern and interest emerge.